Home › Research › Biomarkers
Plasma p-tau217 and neurofilament/p-tau217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration
Benussi A, Huber H, Tan K, Cantoni V, Rivolta J, Cotelli MS, Benedet AL, Blennow K et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-01-08
Topic: Brain proteins, microglia and lab models
Plain-language summary
Introduction Plasma-based biomarkers have shown promise for clinical implementation, but their accuracy in differentiating Alzheimer's disease (AD) from syndromes associated with frontotemporal lobar degeneration (FTLD) has yet to be fully investigated. This study assessed the potential of plasma biomarkers for differential diagnosis. Methods This cohort study included 374 participants (96 AD, 278 FTLD). Plasma phosphorylated tau (p-tau) 217 , neurofilament light chain (NfL), brain-derived tau, glial fibrillary acidic protein, and the amyloid beta 1-42 / 1-40 ratio were measured. Receiver operating characteristic curve analyses assessed diagnostic accuracy, and a three-range threshold approach was used to stratify patients based on the most accurate biomarker. Results Plasma p-tau 217 effectively distinguished AD from FTLD, with the NfL/p-tau 217 ratio showing superior accuracy. The three-range approach identified thresholds with 95% and 97.5% sensitivity and specificity, reducing the need for cerebrospinal fluid testing by 75% and 54%, respectively. Discussion Plasma p-tau 217 and the NfL/p-tau 217 ratio are promising non-invasive biomarkers for differentiating AD from FTLD, suggesting their use as a potential alternative to traditional diagnostic methods. Highlights Plasma phosphorylated tau (p-tau) 217 distinguishes Alzheimer's disease (AD) from frontotemporal lobar degeneration (FTLD) with high accuracy. The neurofilament light chain/p-tau 217 ratio showed the highest accuracy for differentiating AD from FTLD. A three-range threshold reduces the need for invasive cerebrospinal fluid testing or amyloid positron emission tomography imaging.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Benussi, A., Huber, H., Tan, K., Cantoni, V., Rivolta, J., Cotelli, M. S., et al. (2025). Plasma p-tau217 and neurofilament/p-tau217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.14482
Vancouver
Benussi A, Huber H, Tan K, Cantoni V, Rivolta J, Cotelli MS, et al. Plasma p-tau217 and neurofilament/p-tau217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.14482. PMID: 39776166.
BibTeX
@article{benussi2025-39776166,
author = {Benussi, A. and Huber, H. and Tan, K. and Cantoni, V. and Rivolta, J. and Cotelli, M. S. and Benedet, A. L. and Blennow, K. and others},
title = {{Plasma p-tau217 and neurofilament/p-tau217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.14482},
pmid = {39776166},
url = {https://doi.org/10.1002/alz.14482}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Introduction Plasma-based biomarkers have shown promise for clinical implementation, but their accuracy in differentiating Alzheimer's disease (AD) from syndromes associated with frontotemporal lobar degeneration (FTLD) has yet to be fully investigated.
- Results Plasma p-tau 217 effectively distinguished AD from FTLD, with the NfL/p-tau 217 ratio showing superior accuracy.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants374
- Effect size97.5%
- Evidence strengthModerate
How this study scored 76/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 44 of the 58 points we could judge it on, which is 76 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 374 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39776166) |
| Free to read | 2 / 2 | Free to read |
| Points | 44 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 44 of the 58 points we could judge it on is 76 out of 100. |
| Total | 76 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “differentiating”
3 studies in the library carry the topic tag “differentiating”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.